Yahoo Finance

AB2 Bio Completes Enrolment in Pivotal Phase 3 Trial of Tadekinig alfa to Treat Primary Monogenic IL-18 Driven HLH

Potential new treatment option in ultra-rare, life-threatening, primarily pediatric disease with no approved therapies Lausanne (Switzerland), March 7, 2023 -- AB2 Bio Ltd., a biotechnology company ...
Yahoo Finance

AB2 Bio signs U.S. option and licensing agreement with Nippon Shinyaku for Tadekinig alfa for an ultra-rare autoimmune disease

Agreement grants Nippon Shinyaku an option to acquire exclusive U.S. rights to commercialize AB2 Bio’s Tadekinig alfa to treat Primary Monogenic IL-18 driven Hyperinflammatory Syndrome in patients ...
Nasdaq

WuXi Biologics and AB2 Bio Announce Collaboration to Accelerate Commercial-Scale Manufacturing of Tadekinig alfa

Tadekinig alfa is a novel IL-18 binding protein in pivotal Phase 3 testing for orphan disease IL-18 driven monogenic Hemophagocytic Lymphohistiocytosis (HLH) WuXi Biologics to undertake ...
BioWorld

Already a life saver: AB2 Bio advancing its IL-18-binding protein

DUBLIN – Swiss orphan drug developer AB2 Bio Ltd. has obtained dramatic clinical proof of concept for its recombinant interleukin-18-binding protein (IL-18BP) therapy (tadekinig alfa), in an ...
BioWorld

AB2 Bio completes enrollment in pivotal pediatric trial for ultra-rare inflammatory disease

Swiss orphan biotech AB2 Bio Ltd. has completed enrollment in a pivotal phase III trial for its recombinant interleukin-18-binding protein drug tadekinig alfa for an inherited form of the ultra-rare ...
PharmiWeb

AB2 Bio Completes Enrolment in Pivotal Phase 3 Trial of Tadekinig alfa to Treat Primary Monogenic IL-18 Driven HLH

Lausanne (Switzerland), March 7, 2023 -- AB2 Bio Ltd., a biotechnology company developing innovative therapies for the treatment of severe systemic autoinflammatory diseases and conditions driven by ...